Hamlin P, Farber C, Fenske T, et al. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/refractory B cell malignancies. EHA 2017, abstract S773.
Overleving oudere CML-patiënt blijft achter, ook in TKI-tijdperk
jul 2020 | Leukemie, Ouderen